Results 1 to 10 of about 197 (104)
Étude multi-omics des mutations des isocitrates déshydrogénases dans les leucémies aiguës myéloïdes
, 2023 Acute myeloid leukemia (AML) is a hematological malignancy. Despite intensive chemotherapy treatments, the 5-year survival rate of AML patients remains low. This is due to mechanisms of resistance, as well as a high relapse rate.
Hucteau, Alexis
core +2 more sources
Isocitrate Dehydrogenase Genes [PDF]
Deutsches Ärzteblatt international, 2015 The molecular classification and taxonomy of malignant diseases, such as the one successfully applied and published by The Cancer Genome Atlas Project TCGA (http://cancergenome.nih.gov/) for urinary bladder and colorectal cancer, adenocarcinoma of the stomach, and glioblastoma multiforme, provides the opportunity to define so-called driver mutations ...
openaire +2 more sources
Etude des fonctions de CEBPA dans le métabolisme et la réponse aux traitements des leucémies aiguës myéloïdes [PDF]
, 2021 Acute myeloid leukemia (AML) are hematological malignancies characterized by an aberrant proliferation of myeloid progenitor cells that are blocked at an early stage of their differentiation. Leukemogenesis is finely regulated by transcription factor (TF)
Sabatier, Marie
core
Isocitrate Lyase in Green Leaves [PDF]
Plant Physiology, 1973 Isocitrate lyase (EC 4.1.3.1) has been demonstrated in crude dialyzed extracts of healthy spinach (Spinacia oleracea) leaves from commercial sources and wheat (Triticum aestivum) and maize (Zea mays) leaves stored in darkness in the cold room for 1 week.
H R, Godavari, S S, Badour, E R, Waygood
openaire +2 more sources
Journal of Biological Chemistry, 1989 Equilibrium binding studies demonstrate that purified Escherichia coli isocitrate dehydrogenase binds isocitrate, alpha-ketoglutarate, NADP, and NADPH at 1:1 ratios of substrate to enzyme monomer. The phosphorylated enzyme, which is completely inactive, is unable to bind isocitrate but retains the ability to bind NADP and NADPH.
A M, Dean, M H, Lee, D E, Koshland
openaire +2 more sources
Isocitrate dehydrogenase mutations in gliomas [PDF]
Neuro-Oncology, 2015 Over the last decade, extraordinary progress has been made in elucidating the underlying genetic causes of gliomas. In 2008, our understanding of glioma genetics was revolutionized when mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) were identified in the vast majority of progressive gliomas and secondary glioblastomas (GBMs).
Matthew S, Waitkus +2 more
openaire +2 more sources
Isocitrate dehydrogenase mutations in leukemia [PDF]
Journal of Clinical Investigation, 2013 Recent genome-wide discovery studies have identified a spectrum of mutations in different malignancies and have led to the elucidation of novel pathways that contribute to oncogenic transformation. The discovery of mutations in the genes encoding isocitrate dehydrogenase (IDH) has uncovered a critical role for altered metabolism in oncogenesis, and the
Anna Sophia, McKenney, Ross L, Levine
openaire +2 more sources
Nondecarboxylating and Decarboxylating Isocitrate Dehydrogenases: Oxalosuccinate Reductase as an Ancestral Form of Isocitrate Dehydrogenase [PDF]
Journal of Bacteriology, 2008 ABSTRACTIsocitrate dehydrogenase (ICDH) fromHydrogenobacter thermophiluscatalyzes the reduction of oxalosuccinate, which corresponds to the second step of the reductive carboxylation of 2-oxoglutarate in the reductive tricarboxylic acid cycle. In this study, the oxidation reaction catalyzed byH. thermophilusICDH was kinetically analyzed. As a result, a
Miho, Aoshima, Yasuo, Igarashi
openaire +2 more sources
, 2023 PharmacieLes premières mutations IDH ont été identifiées lors d’une analyse génomique de glioblastomes, puis rapidement, des mutations des gènes IDH1/2 ont été mises en évidences dans divers autres types de tumeurs comme la LAM.
Noubli, Halima
core
Study of CEBPA functions in metabolism and response to treatment in acute myeloid leukemia
, 2021 Les leucémies aiguës myéloïdes (LAM) sont des hémopathies malignes rares causées par une prolifération anormale et non contrôlée de progéniteurs myéloïdes bloqués à un stade précoce de leur différenciation.
Sabatier, Marie
core